Zoetis Price Target Announced at $220.00/Share by BTIG
Zoetis Analyst Ratings
BTIG Initiates Zoetis(ZTS.US) With Buy Rating, Announces Target Price $220
Buy Rating Affirmed: Sangamo's Hemophilia A Gene Therapy Poised for Success With Pfizer Partnership
Piper Sandler Maintains Viatris(VTRS.US) With Hold Rating, Maintains Target Price $13
Jefferies Maintains Zoetis(ZTS.US) With Buy Rating, Cuts Target Price to $200
Buy Rating Affirmed for Zoetis Amidst Favorable Market Dynamics and Strong Growth Potential
Johnson & Johnson Analyst Ratings
Daiwa Downgrades Johnson & Johnson to Neutral From Outperform, Adjusts Price Target to $150 From $160
Axsome Therapeutics Price Target Maintained With a $131.00/Share by RBC Capital
Axsome Therapeutics Analyst Ratings
Eli Lilly, Novo Are Weight-Loss Winners. Rivals Won't Be an Issue for Years: Analyst. -- Barrons.com
Guggenheim Adjusts Johnson & Johnson's Price Target to $156 From $160, Maintains Neutral Rating
RBC Capital Reaffirms Their Buy Rating on Axsome Therapeutics (AXSM)
Intra-Cellular Therapies Analyst Ratings
Needham Maintains Buy on Intra-Cellular Therapies, Raises Price Target to $100
Buy Rating Affirmed for Johnson & Johnson on Strong Growth and Strategic Acquisitions
Johnson & Johnson Analyst Ratings
Viatris Analyst Ratings
HSBC Adjusts Price Target on Johnson & Johnson to $174 From $170, Maintains Buy Rating